RTA compliance certificate filed for Q2 FY27, no physical share certificates received

Compliance View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.7%Reaction day

₹0.27

prior close

₹0.26

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%+2.4% vs market

Other Financial Services peers, median of 84sector+0.0%+3.7% vs sector

On the reaction day the stock moved 2.4 pts more than Nifty Microcap 250 and 3.7 pts more than its Other Financial Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+3.8

15m

+3.8

30m

+3.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.7+1.3+2.4+0.0+3.7

Next day

+3.7+1.1+2.6+0.0+3.7

+3.7-1.7+5.4-0.0+3.7

-3.7-1.5-2.3-0.9-2.8

-7.4-0.6-6.8-1.0-6.4

+3.7-0.4+4.1-0.8+4.5

-3.7-1.4-2.3-1.4-2.3

15d

-7.4pendingpending-5.4-2.0

—————

UpDownMarket · Nifty Microcap 250Sector · Other Financial Services peers, median of 84Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biogen Pharmachem Industries submitted the Regulation 74(5) compliance certificate for the quarter ended 30 September 2026, filed by their Registrar Satellite Corporate Services. The RTA confirmed that no physical share certificates were received for dematerialization during the quarter. This is a routine procedural filing with no business or financial impact.

Likely market impact

Routine regulatory compliance filing. No material impact on shareholders or stock price. Nil demat activity reported for the quarter.